• REVLIMID® is the first and only medicine granted positive CHMP opinion for post-Autologous Stem Cell Transplantation (ASCT) maintenance therapy in MM

• The new indication expands the availability of REVLIMID® across the disease continuum of MM

BOUDRY, Switzerland-Monday, January 30th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of REVLIMID® as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation (ASCT). Once approved by the European Commission, REVLIMID® will be the first and only licensed maintenance treatment available to these patients.

Multiple myeloma i ... Read more »

AMSTERDAM-Friday, January 27th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Pershing Square Holdings, Ltd. (ticker: PSH:NA) posted today its Annual Investor Update Presentation on its website, https://www.pershingsquareholdings.com/company-reports/letters-to-shareholders/. The presentation includes a performance review, an update of the fund’s portfolio and an organizational update.

About Pershing Square Holdings, Ltd.

Pershing Square Holdings, Ltd. (PSH:NA) is an investment holding company structured as a closed end fund that makes concentrated investments principally in North American companies.

Contacts

Maitland
James Devas, +44 20 7379 5151
Media-pershingsquareholdings@maitland.co.uk

Permalink : http://me-newswire.net/news/3260/en